

Minutes SSG board meeting (TC) September 27, 2018

Participants:

Thomas Baad-Hansen

Mikael Eriksson

Hans Kristian Haugland

Jukka Kanerva

Fredrik Mertens

Eva-Mari Olofsson

Kirsten Sundby Hall

1. Approval of minutes from the last meeting

The minutes from the last meeting were approved.

2. Economy

Fredrik presented the latest figures. The cash holdings are currently 833 061 SEK, i.e., approximately 635 000 SEK less than at our previous meeting in May. Mikael will have discussions with Novartis regarding amendments to the payment plan for SSG XXII, in order to minimize the gap between expenses (mainly patient registration fees) and income (achieved milestones). Furthermore, the SSG will send monthly bills to Novartis for costs related to the office, data management, etc.

The costs of the SSG XXII trial may generate a temporary deficit. This has been communicated to the head of the department at Lund University that hosts the SSG office and money.

An application to the Cancerfonden for 2019-2020 has been submitted, but a decision will not be reached until October-November.

As before, the need for new financing was discussed.

3. Working group meeting

To be held in Malmö 3-4 December, 2018.

Much of the program for the general assembly has been settled. The subcommittees have to send their program no later than October 1.

On December 2 we will have a board meeting at 17.00. To be discussed among other issues is a visiting fellow program.

The cost for the meeting will be a registration fee of 2600 SEK. For those who only visit the visceral and retroperitoneal sarcoma working group meeting there will be a fee of 500 SEK. We anticipate around 75 participants in total.

4. SSG Board Working Guidelines

Kirsten and Mikael have put down guidelines for future boards and board members. The initiative was applauded and all board members agreed.

Bergen, 8. October 2018 Hans Kristian Haugland